Skip to main content

Table 5 Drug Resistance Among 559 Participants with MDR-TB, by Prior Drug of interest and MDR-TB Treatment Status

From: Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

Drug Received Any Prior MDR-TB Treatment, N = 267a Received No Prior MDR-TB Treatment, N = 289a All Participants, N = 559a Χ2 Test
  # Resistant / # Tested (%)b # Resistant / # Tested (%)b # Resistant / # Tested (%)b p-value
Isoniazid 246 / 248 (99.2) 217 / 219 (99.1) 465 / 469 (99.1) 1.000
Rifampin 289 / 289 (100) 267 / 267 (100) 559 / 559 (100) 1.000
Pyrazinamide 185 / 228 (81.1) 176 / 213 (82.6) 363 / 443 (81.9) 0.778
Ethambutol 212 / 237 (89.5) 178 / 219 (81.3) 392 / 458 (85.6) 0.019
Streptomycin 167 / 177 (94.4) 91 / 100 (91.0) 260 / 279 (93.2) 0.417
Ofloxacin 183 / 233 (78.5) 141 / 211 (66.8) 326 / 446 (73.1) 0.008
Moxifloxacin (low) 157 / 229 (68.6) 122 / 208 (58.7) 281 / 439 (64.0) 0.040
Moxifloxacin (high) 34 / 145 (23.4) 30 / 178 (16.9) 65 / 324 (20.1) 0.181
Kanamycin 73 / 244 (29.9) 35 / 217 (16.1) 110 / 463 (23.8) < 0.001
Amikacin 51 / 225 (22.7) 23 / 206 (11.2) 76 / 433 (17.6) 0.002
Capreomycin 48 / 235 (20.4) 22 / 212 (10.4) 72 / 449 (16.0) 0.005
Ethionamide 150 / 231 (64.9) 122 / 218 (56.0) 274 / 451 (60.8) 0.065
PAS 72 / 231 (31.2) 28 / 217 (12.9) 101 / 450 (22.4) < 0.001
Clofazimine 8 / 219 (3.7) 3 / 204 (1.5) 11 / 425 (2.6) 0.270
Linezolid 13 / 136 (9.6) 6 / 171 (3.5) 20 / 308 (6.5) 0.052
  1. aAll Participants column includes 3 participants for whom the history of prior therapy was not documented
  2. bPercentages reported reflect number of participants with resistance divided by number of participants who completed susceptibility testing for each drug. As a result, the number of participants in the denominator is not the same in all rows